经导管动脉化疗栓塞联合热消融治疗肝转移瘤
回顾性研究纳入1998年8月至2015年9月接受TACE联合消融治疗的42例肝转移瘤患者(44个病灶),中位随访10.3个月;mRECIST评估41个病灶中完全缓解78.0%、部分缓解19.5%、进展2.4%,1年局部无复发率61%、2年50%,1年总生存率55%、2年30%(中位总生存14.5个月),主要并发症发生率19%。
要点
- TACE联合消融治疗肝转移瘤,mRECIST完全缓解率达78.0%(32/41个可评估病灶)。
- 1年局部无复发率61%、2年50%;1年总生存率55%、2年30%,中位总生存14.5个月。
- 主要并发症发生率19%,包括肝脓肿3例、发热住院2例等。
核心结论
- TACE联合消融作为多学科治疗策略的一部分,对直径不超过8 cm的肝转移瘤可实现有效的局部肿瘤控制;主要并发症发生率为19%。
研究设计与样本
- 回顾性研究,纳入1998年8月至2015年9月接受TACE后消融治疗的42例肝转移瘤患者(12例女性、30例男性,年龄62.9±11.9岁),共治疗44个肝转移灶,统计方法包括Kaplan-Meier估计、Cox回归及Fisher精确检验、Wilcoxon秩和检验或log rank检验。
诊断标准与关键数值
- 采用mRECIST评估肿瘤反应,44个治疗病灶中41个可评估:完全缓解32个(78.0%)、部分缓解8个(19.5%)、进展1个(2.4%);中位索引病灶大小4.7 cm(范围1.5–8.0 cm)。
临床应用与阅片要点
- 作者认为TACE联合消融作为多学科治疗策略的一部分,对直径不超过8 cm的肝转移瘤可实现有效的局部肿瘤控制;主要并发症发生率为19%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The purpose of the study was to evaluate safety, time to recurrence, and overall survival (OS) in patients with liver metastases (LM), treated with transarterial chemoembolization (TACE) followed by ablation.
MATERIALS AND METHODS: This retrospective study included all patients with LM treated with combined TACE and ablation from August 1998 to September 2015. Forty-two patients (12 women, 30 men; age 62.9 ± 11.9 years) were treated for 44 LMs. Tumor characteristics, imaging response to treatment, recurrence, and OS data were reviewed. Statistical analysis included Kaplan-Meier estimation, Cox regression and Fisher's exact, Wilcoxon rank sum, or log rank tests.
RESULTS: Median follow-up was 10.3 months. Eighteen patients had 1 hepatic lesion, 16 had 2-5, and 8 had > 5. Median index lesion size was 4.7 cm (range 1.5-8 .0 cm). Tumor response (mRECIST) was available for 41/44 treated lesions, with CR in 32 (78.0%), PR in 8 (19.5%), and PD in 1 (2.4%). Long-term imaging follow-up was available for 38 patients. Freedom from local recurrence was 61% at 1 year and 50% at 2 years. OS was 55% at 1 year and 30% at 2 years (median OS, 14.5 months). Tumor size and histology were not predictors of time to progression or OS. Complications occurred in 19 patients (45%). Major complications occurred in 19% of patients and included hospitalization for fever (n = 2), hepatic abscess (n = 3) and fall requiring transfusion, portal vein thrombus causing lobar infarct, biliary fistula, and retroperitoneal hematoma (n = 1 each).
CONCLUSIONS: Combined TACE and ablation is effective for local tumor control of liver metastases up to 8 cm when part of a multidisciplinary treatment strategy. Major complications occurred in 19% of patients.
引用
- Alexander ES, Mick R, Nadolski GJ, et al. Combined chemoembolization and thermal ablation for the treatment of metastases to the liver. Abdom Radiol (NY). 2018. PMID: 29500644. doi:10.1007/s00261-018-1536-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。